肺癌患者中系统性纵隔分期与靶向EBUS-TBNA分期的比较
回顾性研究107例PET/CT诊断为N2的非小细胞肺癌患者,评估系统性EBUS-TBNA纵隔分期(对所有可见且≥5 mm的N3至N1站淋巴结取样,不论PET/CT特征)的准确性,并与仅对FDG高摄取淋巴结取样的靶向策略模拟比较。系统性EBUS-TBNA灵敏度94%、特异度100%、阴性预测值90%、阳性预测值100%、总准确率96%,在14例(13%)中提供额外重要信息。作者推荐临床实践中采用系统性取样而非靶向取样。
要点
- 系统性EBUS-TBNA灵敏度94%、特异度100%、阴性预测值90%、阳性预测值100%、总准确率96%。
- 系统性取样较靶向取样在14例(13%)中提供额外重要信息:3例N3未被发现,11例N2b被误判为N2a。
- 作者推荐临床实践中采用系统性纵隔取样而非靶向取样,不论PET/CT特征。
核心结论
- 在临床实践中,推荐采用系统性EBUS-TBNA纵隔取样而非靶向取样,不论PET/CT特征。
研究设计与样本
- 回顾性研究,纳入107例PET/CT诊断为N2的非小细胞肺癌患者,均接受系统性EBUS-TBNA纵隔分期。
- 将系统性EBUS-TBNA结果与仅对PET/CT上FDG高摄取淋巴结取样的模拟情景进行比较。
主要发现
- 系统性EBUS-TBNA发现N3病变3例、N2病变60例(42例单站或N2a,18例多站或N2b)、N0/N1病变44例。
- 44例N0/N1中7例接受纵隔镜检查未显示纵隔病变,其中6例后续肺切除亦未显示纵隔病变。
- 34例EBUS-TBNA后N0/N1患者直接接受肺切除:30例为N0/N1,4例为N2(1例N2b其PET/CT显示N2a病变,3例N2a)。
- 系统性EBUS-TBNA的灵敏度94%、特异度100%、阴性预测值90%、阳性预测值100%、总准确率96%。
- 与靶向EBUS-TBNA相比,系统性EBUS-TBNA在14例(13%)中提供额外重要临床信息:3例N3未被发现,11例N2b被分期为N2a。
关键数值与推荐
- 系统性EBUS-TBNA取样定义为对所有可见且测量≥5 mm的N3至N1站淋巴结取样,不论PET/CT特征。
- 靶向EBUS-TBNA取样定义为仅对18F-氟脱氧葡萄糖(FDG)高摄取淋巴结取样。
- 系统性EBUS-TBNA灵敏度94%、特异度100%、阴性预测值90%、阳性预测值100%、总准确率96%。
临床怎么用
- 作者推荐临床实践中采用系统性纵隔取样而非靶向取样,不论PET/CT特征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the accuracy of systematic mediastinal staging by endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) (sampling of all visible nodes measuring ≥5 mm from stations N3 to N1 regardless of their positron emission tomography/computed tomography [PET/CT] features) and compare this staging approach with targeted EBUS-TBNA staging (sampling only 18F-fluorodeoxyglucose [FDG]-avid nodes) in patients with N2 non-small cell lung cancer on PET/CT. METHODS: Retrospective study of 107 patients who underwent systematic EBUS-TBNA mediastinal staging. The results were compared with those of a hypothetical scenario where only FDG-avid nodes on PET/CT would be sampled. RESULTS: Systematic EBUS-TBNA sampling demonstrated N3 disease in 3 patients, N2 disease in 60 (42 single-station or N2a, 18 multiple-station or N2b) and N0/N1 disease in 44. Of these 44, 7 underwent mediastinoscopy, which did not show mediastinal disease; 6 of the 7 proceeded to lung resection, which also showed no mediastinal disease. Thirty-four N0/N1 patients after EBUS-TBNA underwent lung resection directly: N0/N1 was found in 30 and N2 in 4 (1 N2b with a PET/CT showing N2a disease, 3 N2a). Sensitivity, specificity, negative predictive value, positive predictive value, and overall accuracy of systematic EBUS-TBNA were 94%, 100%, 90%, 100% and 96%, respectively. Compared with targeted EBUS-TBNA, systematic EBUS-TBNA sampling provided additional important clinical information in 14 cases (13%): 3 N3 cases would have passed unnoticed, and 11 N2b cases would have been staged as N2a. CONCLUSIONS: In clinical practice, systematic sampling of the mediastinum by EBUS-TBNA, regardless of PET/CT features, is to be recommended over targeted sampling.
引用
- Sanz-Santos J, Serra P, Torky M, et al. Systematic Compared With Targeted Staging With Endobronchial Ultrasound in Patients With Lung Cancer. Ann Thorac Surg. 2018. PMID: 29630875. doi:10.1016/j.athoracsur.2018.02.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。